Hovione's TwinCaps(R) Dry-powder Inhaler Approved In Japan As Part Of Inavir(R) Influenza Treatment
Main Category: Infectious Diseases / Bacteria / VirusesAlso Included In: Respiratory / Asthma; Regulatory Affairs / Drug Approvals; Medical Devices / Diagnostics
Article Date: 15 Sep 2010 - 4:00 PDT
'Hovione's TwinCaps(R) Dry-powder Inhaler Approved In Japan As Part Of Inavir(R) Influenza Treatment'
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Hovione is announcing the approval in Japan of Inavir(R), Dry Powder Inhaler 20mg, for treatment of influenza. This approval has been granted to Daiichi Sankyo Company Ltd, a licensee of Hovione for the TwinCaps(R) inhaler which delivers the drug to the lungs.
Hovione developed the TwinCaps(R) inhaler specifically for this indication. Inavir(R) directly delivers the drug to the infected airways of influenza patients, and a single inhaled dose has proven to be as effective as a five-day course of oseltamivir for treatment of influenza. Daiichi Sankyo has announced it is confident that Inavir(R) will be an important alternative for treating influenza. According to Hovione, the low cost of the device means the inhaler can be disposable and is thus ideally suited for the treatment of lung infection. As bacteria or viruses are present in the airways, a disposable inhaler may be safer than a re-usable one.
Peter Villax, TwinCaps(R) inventor and Hovione Vice-President said "This approval will boost visibility for TwinCaps(R), an inhaler designed for extreme ease of use, as would be necessary in the case of a pandemic."
Jason Suggett, Hovione Director of Pharma Operations said "We have a number of inhaled drug product development projects ongoing, and our in-house particle engineering expertise means that we can deliver large doses of powder from inhaler devices."
About Hovione. Hovione is a leading developer of inhaled drug products, with experience in anti-virals and proteins delivered by inhalation, as well as inhaler development. It is an international company with 51 years' experience in Active Pharmaceutical Ingredient integrated development and compliant manufacture, from molecule to unit dose. In the inhalation area, Hovione is the only independent company offering such a broad range of services.
Source: Hovione
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.
MLA
31 May. 2012. <http://www.medicalnewstoday.com/releases/201110.php>
APA
http://www.medicalnewstoday.com/releases/201110.php.
Please note: If no author information is provided, the source is cited instead.
Add Your Opinion On This Article
'Hovione's TwinCaps(R) Dry-powder Inhaler Approved In Japan As Part Of Inavir(R) Influenza Treatment'Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



